Fundraising Fox
Linus Bio
New York, US · Founded 2020 · 31 employees on LinkedIn · 4 known investors
Find your way into Linus Bio
Sign up to see every warm intro you have to Linus Bio
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Linus Bio team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
LinusBio develops precision medicine diagnostics based on exposome sequencing to identify biomarkers for complex conditions including autism spectrum disorder, amyotrophic lateral sclerosis, inflammatory bowel disease, and other diseases. The company serves physicians and patients seeking earlier detection and intervention for conditions that historically lacked molecular diagnostic endpoints.
Founders & leadership
Linus Bio was founded in 2020 by Manish Arora.
Board
Investors · 4
How we know: Bow Capital's portfolio page · the company's own site · funding news · apnews.com · Not right? Tell us
How we know: GreatPoint Ventures's portfolio page · board seat on SEC Form D · apnews.com · the VCSheet dataset · Not right? Tell us
Also in the syndicate · 1
Funding
SEC filings, press & company announcements$47.6M disclosed across 4 of 6 rounds · 2022–2024
- Undisclosed amountSeries AApr 2023
Bow Capital (lead), GreatPoint Ventures (lead), Divergent Investments
Source ↗ - Undisclosed amountSeries AMar 2023Source ↗
- $16MSeries AJan 2023 · 4 sources
Bow Capital (lead), GreatPoint Ventures (lead), Divergent Investments, the David Bellet Family Office
Source ↗
▶$6.1MraisedAug 2024 · 4 investors · BiotechnologyRule 506(b)
- Rafi SyedDirector
- Amol DeshpandeDirector
- Ashok KrishnamurthiDirector
- Manish AroraExecutive Officer, Director
- Offering amount
- $10M
- Amount sold
- $6.1M
- First sale
- Jul 2024
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$8MraisedMay 2023 · 3 investors · BiotechnologyRule 506(b)
- Manish AroraExecutive Officer, Director
- Rafi SyedDirector
- Ashok KrishnamurthiDirector
- Amol DeshpandeDirector
- Offering amount
- $8M
- Amount sold
- $8M
- First sale
- May 2023
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$17.5MraisedMar 2022 · 14 investors · BiotechnologyRule 506(b)
- Jan GlassnerExecutive Officer, Director
- Ashok KrishnamurthiDirector
- Rafi SyedDirector
- Manish AroraExecutive Officer, Director
- Offering amount
- $17.5M
- Amount sold
- $17.5M
- First sale
- Mar 2022
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Linus Bio do?
- LinusBio develops precision medicine diagnostics based on exposome sequencing to identify biomarkers for complex conditions including autism spectrum disorder, amyotrophic lateral sclerosis, inflammatory bowel disease, and other diseases. The company serves physicians and patients seeking earlier detection and intervention for conditions that historically lacked molecular diagnostic endpoints.
- Who founded Linus Bio?
- Linus Bio was founded by Manish Arora in 2020.
- Who are Linus Bio's investors?
- Linus Bio's investors include Bow Capital, GreatPoint Ventures, Divergent Investments.
- How much funding has Linus Bio raised?
- Linus Bio has disclosed $47.6M raised across 4 of its 6 known rounds.
- Where is Linus Bio headquartered?
- Linus Bio is headquartered in New York, US.